About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in North Carolina | 17,526 Studies Near You | Clareo Health

Clinical Trials LocationsNorth Carolina

Clinical Trials in North Carolina

Discover 17,526 clinical trials near North Carolina. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1601-1620 of 17,526 trials

RECRUITINGNA41 miles

Autologous Muscle Fiber Fragment Injections

NCT05396456

To regenerate functional anal sphincter muscle using muscle fiber fragments that contain muscle precursor cells (MPCs)

Fecal Incontinence

Wake Forest University Health Sciences10 participantsStarted Jan 2023

Winston-Salem, North Carolina, United States

RECRUITINGNA41 miles

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794

A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.

Parkinson DiseaseFreezing of GaitDeep Brain Stimulation

CereGate Inc.41 participantsStarted Apr 2022

Redwood City, California, United States • Aurora, Colorado, United States • Miami, Florida, United States +4 more locations

Find Trials by Condition in North Carolina

Breast Cancerin North Carolina Lung Cancerin North Carolina Prostate Cancerin North Carolina Colorectal Cancerin North Carolina Melanomain North Carolina Leukemiain North Carolina Lymphomain North Carolina Pancreatic Cancerin North Carolina Ovarian Cancerin North Carolina Brain Cancerin North Carolina

Data from ClinicalTrials.govTerms

RECRUITINGPhase 457 miles

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07219121

To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.

ProteinuriaImmunoglobulin A (IgA) NephropathyFocal Segmental Glomerulosclerosis+1 more

Travere Therapeutics, Inc.20 participantsStarted Oct 2025

Birmingham, Alabama, United States • New York, New York, United States • Morrisville, North Carolina, United States +6 more locations

RECRUITINGPhase 257 miles

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed, Carboplatin) in the first-line treatment of participants with newly diagnosed metastatic non-squamous NSCLC. The trial consists of 3 Parts, a non-randomized Safety-run-in part (Part A) and the subsequent randomized Ph2b trial with 2 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor

CatalYm GmbH107 participantsStarted Aug 2025

Birmingham, Alabama, United States • Los Angeles, California, United States • New Haven, Connecticut, United States +22 more locations

RECRUITINGPhase 2181 miles

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT06660355

Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of therapy based on a prior large, randomized phase III study. Given this evidence of safety and efficacy in the early refractory setting (after prednisone failure), Ruxolitinib represents an ideal agent to test in the primary therapy setting. Here investigators propose a phase 2 randomized study to compare Ruxolitinib to prednisone as a first-line therapy in the treatment of chronic GVHD.

Chronic Graft-versus-host Disease (cGVHD)

H. Lee Moffitt Cancer Center and Research Institute120 participantsStarted Dec 2024

Miami, Florida, United States • Tampa, Florida, United States • Charlottesville, Virginia, United States +1 more locations

COMPLETED186 miles

Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

NCT03981289

Limb Girdle Muscular Dystrophy comprise a group of disorders made up of over 30 mutations which share a common phenotype of progressive weakness of the shoulder and hip girdle muscles. While the individual genetic mutations are rare, as a cohort, LGMDs are one of the four most common muscular dystrophies. The overall goal of project 1 is to define the key phenotypes as measured by standard clinical outcome assessments (COAs) for limb girdle muscular dystrophies (LGMD) to hasten therapeutic development.

Limb Girdle Muscular DystrophyMuscular Dystrophies

Virginia Commonwealth University116 participantsStarted Jun 2019

Irvine, California, United States • Aurora, Colorado, United States • Iowa City, Iowa, United States +7 more locations

COMPLETEDPhase 4192 miles

Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

NCT06563102

The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment duration will be 12 weeks. * The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.

AstraZeneca101 participantsStarted Sep 2024

Phoenix, Arizona, United States • Tucson, Arizona, United States • Lancaster, California, United States +13 more locations

RECRUITINGPhase 2213 miles

A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

NCT06450639

The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD age ≥ 8 to \< 18 years old receiving corticosteroid therapy.

Duchenne Muscular Dystrophy

Hoffmann-La Roche50 participantsStarted Apr 2025

Little Rock, Arkansas, United States • Sacramento, California, United States • Atlanta, Georgia, United States +22 more locations

COMPLETEDPhase 3232 miles

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453

This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized. Part 1: Patients will be randomized in a 1:1:1 ratio to one of 3 treatment arms: 1. LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm) 2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or 3. vemurafenib 960 mg BID (denoted as vemurafenib arm) Part 2: Patients will be randomized in a 3:1 ratio to one of the 2 treatment arms: 1. LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or 2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm)

Pfizer921 participantsStarted Sep 2013

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +279 more locations

COMPLETEDPhase 1/2261 miles

Study of INKmune in Patients With mCRPC (CaRe Prostate)

NCT06056791

This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.

CancerMetastatic Castration-resistant Prostate CancermCRPC

Inmune Bio, Inc.12 participantsStarted Nov 2023

Los Angeles, California, United States • Los Angeles, California, United States • Las Vegas, Nevada, United States +5 more locations

RECRUITINGPhase 1261 miles

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

NCT06759649

The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.

NeoplasmCancer, Malignant Tumors

Compugen Ltd200 participantsStarted Jan 2025

New Haven, Connecticut, United States • Boston, Massachusetts, United States • Grand Rapids, Michigan, United States +8 more locations

Active Not RecruitingPhase 1261 miles

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Advanced CancerAdvanced MalignanciesBladder Cancer+9 more

Arcus Biosciences, Inc.40 participantsStarted Oct 2023

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Lake City, Florida, United States +12 more locations

RECRUITINGPhase 1/2270 miles

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Non Small Cell Lung Carcinoma

AbbVie252 participantsStarted Mar 2025

Fullerton, California, United States • Oxnard, California, United States • Santa Monica, California, United States +52 more locations

RECRUITINGPhase 3276 miles

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006

This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).

Gastroesophageal-junction CancerMonoclonal AntibodyGastric Cancer+1 more

Shanghai Henlius Biotech550 participantsStarted Nov 2024

Anaheim, California, United States • Los Alamitos, California, United States • Greeley, Colorado, United States +205 more locations

RECRUITINGPhase 2287 miles

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

NCT07285018

The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Diabetic Peripheral Neuropathic Pain

Eli Lilly and Company150 participantsStarted Feb 2026

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +34 more locations

RECRUITINGNA291 miles

Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction

NCT07273773

This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction. The study follows patients implanted with the Rigicon Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis for up to 3 years after implantation.

Erectile Dysfunction (ED)

Rigicon, Inc.182 participantsStarted Jan 2026

Coral Gables, Florida, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +4 more locations

Active Not RecruitingPhase 3291 miles

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

NCT03992430

Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 200 mg/kg) of eteplirsen compared with that of the 30 mg/kg dose of eteplirsen, in approximately 144 participants with genetically confirmed deletion mutations amenable to treatment by skipping exon 51.

Muscular Dystrophy, Duchenne

Sarepta Therapeutics, Inc.160 participantsStarted Jul 2020

Birmingham, Alabama, United States • Gainesville, Florida, United States • Atlanta, Georgia, United States +56 more locations

TERMINATEDPhase 3308 miles

Open-Label Extension of EryDex Study IEDAT-04-2022

NCT06664853

This is an international, multi-center, prospective, open-label, non-comparative study to provide EryDex treatment to ataxia telangiectasia (A-T) patients who complete the IEDAT-04-2022 trial on the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).

Ataxia Telangiectasia

Quince Therapeutics S.p.A.101 participantsStarted Dec 2024

Los Angeles, California, United States • Baltimore, Maryland, United States • New Brunswick, New Jersey, United States +18 more locations

RECRUITINGPhase 1/2346 miles

SMP-3124LP in Adults With Advanced Solid Tumors

NCT06526819

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

Sumitomo Pharma America, Inc.120 participantsStarted Aug 2024

Los Angeles, California, United States • Denver, Colorado, United States • Chicago, Illinois, United States +7 more locations

RECRUITINGPhase 1667 miles

A Study of V118E in Healthy Participants (V118E-003)

NCT07168915

Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.

Merck Sharp & Dohme LLC126 participantsStarted Oct 2025

Hallandale, Florida, United States • South Miami, Florida, United States • Springfield, Missouri, United States +1 more locations

PreviousPage 81 of 877Next

Diabetes

in North Carolina

Heart Diseasein North Carolina